rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Rohan Palekar

Director

Company insider

Files Form 4 as: Director, Neurogene; Chief Executive Officer, 89bio; SVP & Chief Commercial Officer, Avanir Pharmaceuticals; Chief Commercial Officer, Medivation.

Every Form 4 they filed

In numbers

Trades disclosed
115
Buys
9
Sells
16
Bought
$388K
Sold
$4.4M
Companies
4
Companies where not an officer
1
First trade
14 Jan 2008
Last trade
20 Feb 2026
Last filed
24 Feb 2026

Companies traded

Where they are an officer
89bioDirector, Officer · last 30 Oct 20256 buys · 5 sells
Avanir PharmaceuticalsOfficer · last 28 Nov 20143 buys · 2 sells
MedivationOfficer · last 20 Apr 20110 buys · 9 sells
Everywhere else they filed: board seats, 10% stakes, other companies
NGNE NeurogeneDirector · Biotechnology · last 20 Feb 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
01Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
20 Feb 2026filed 24 Feb 2026NGNE Neurogeneoption or derivative · BiotechnologySEC FORM 4 Code A—12,050 at $0.00filing
20 Feb 2026filed 24 Feb 2026NGNE Neurogeneoption or derivative · BiotechnologySEC FORM 4 Code A—12,050 at $0.00filing
30 Oct 2025filed 30 Oct 202589biooption or derivativeSEC FORM 4 Code D—120,231 at $0.00filing
30 Oct 2025filed 30 Oct 202589biooption or derivativeSEC FORM 4 Code D—132,242 at $0.00filing
30 Oct 2025filed 30 Oct 202589biooption or derivativeSEC FORM 4 Code D—170,000 at $0.00filing
30 Oct 2025filed 30 Oct 202589biooption or derivativeSEC FORM 4 Code D—203,750 at $0.00filing
30 Oct 2025filed 30 Oct 202589biooption or derivativeSEC FORM 4 Code D—220,000 at $0.00filing
30 Oct 2025filed 30 Oct 202589biooption or derivativeSEC FORM 4 Code D—300,000 at $0.00filing
30 Oct 2025filed 30 Oct 202589biooption or derivativeSEC FORM 4 Code D—605,000 at $0.00filing
30 Oct 2025filed 30 Oct 202589biooption or derivativeSEC FORM 4 Code D—848,000 at $0.00filing
30 Oct 2025filed 30 Oct 202589bioSEC FORM 4 Code A—125,000 at $0.00filing
30 Oct 2025filed 30 Oct 202589bioSEC FORM 4 Code U—934,273filing
1 Aug 2025filed 5 Aug 202589bioSEC FORM 4 Code F$511K55,836 at $9.16filing
12 Jun 2025filed 13 Jun 2025NGNE Neurogeneoption or derivative · BiotechnologySEC FORM 4 Code A—12,050 at $0.00filing
17 Feb 2025filed 19 Feb 202589bioSEC FORM 4 Code F$34K3,249 at $10.57filing
9 Feb 2025filed 11 Feb 202589bioSEC FORM 4 Code F$102K8,946 at $11.41filing
1 Feb 2025filed 4 Feb 202589biooption or derivativeSEC FORM 4 Code A—848,000 at $0.00filing
1 Feb 2025filed 4 Feb 202589bioSEC FORM 4 Code A—212,000 at $0.00filing
1 Feb 2025filed 4 Feb 202589bioSEC FORM 4 Code A—200,000 at $0.00filing
1 Feb 2025filed 4 Feb 202589bioSEC FORM 4 Code F$92K9,598 at $9.60filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed25

Buys in green, sells in red, by the company’s sector.

Related people

Lota S. ZothDirector · Director at 89bio, filing Form 4 there in the last year
Michael R. HaydenDirector · Director at 89bio, filing Form 4 there in the last year
Martin BablerDirector · Director at 89bio, filing Form 4 there in the last year
Steven AltschulerDirector · Director at 89bio, filing Form 4 there in the last year
Derek DiRoccoDirector · Director at 89bio, filing Form 4 there in the last year